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Abstract
Background:  Nausea and vomiting is a problem for children after neurosurgery and those
requiring posterior fossa procedures appear to have a high incidence. This clinical observation has
not been quantified nor have risk factors unique to this group of children been elucidated.
Methods: A six year retrospective chart audit at two Canadian children's hospitals was conducted.
The incidence of nausea and vomiting was extracted. Hierarchical multivariable logistic regression
was used to quantify risk and protective factors at 120 hours after surgery and early vs. late
vomiting.
Results: The incidence of vomiting over a ten day postoperative period was 76.7%. Documented
vomiting ranged from single events to greater than 20 over the same period. In the final
multivariable model: adolescents (age 12 to <17) were less likely to vomit by 120 hours after
surgery than other age groups; those who received desflurane, when compared to all other volatile
anesthetics, were more likely to vomit, yet the use of ondansetron with desflurane decre kelihood.
Children who had intraoperative ondansetron were more likely to vomit in the final multivariable
model (perhaps because of its use, in the clinical judgment of the anesthesiologist, for children
considered at risk). Children who started vomiting in the first 24 hours were more likely to be
school age (groups 4 to <7 and 7 to <12) and receive desflurane. Nausea was not well documented
and was therefore not analyzed.
Conclusion: The incidence of vomiting in children after posterior fossa surgery is sufficient to
consider all children requiring these procedures to be at high risk for POV. Nausea requires better
assessment and documentation.
Background
The successful management of nausea and vomiting is an
important component in the care of children after surgery.
Postoperative nausea and vomiting (PONV) may cause
discomfort and distress, put pressure on surgical incisions,
cause dehydration and electrolyte imbalance, delay recov-
ery, and prolong hospitalization [1,2]. Children are at
high risk for experiencing PONV [3-5], and estimates of
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postoperative vomiting (POV) for children requiring
craniotomy have been as high as 66% [6]. The effects of
increased intracranial pressure during retching and vomit-
ing may be especially problematic after craniotomy [7].
Therefore, children after craniotomy may be at particular
risk for experiencing PONV that result in suffering and
other negative outcomes.
Tramer [8] describes three rules of practice to ensure opti-
mal management of PONV: identify those at risk using
predictive factors; modify anaesthesia techniques to keep
the baseline risk as low as possible; and administer anti-
emetics rationally with consideration to their efficacy,
additive properties, and adverse effects. Of these, Tramer
concedes that knowledge of risk factors remains an under-
researched area, especially for children. In one of the few
multivariable studies of predictive factors of POV in chil-
dren [9], the combination of the following factors could
be used to determine a child's risk of POV after surgery:
history of POV in the child or PONV in father, mother or
siblings; age over three years; length of surgery over thirty
minutes; and strabismus surgery. The results of this study
were further validated in a separate group of children [10]
and were predictive of POV even when strabismus surgery
was not in the prognostic model. These studies did not
have the participation of children requiring craniotomy.
However, if the prognostic models were used to predict
POV in children after craniotomy, age and history of POV
or PONV in father, mother, or siblings would be the only
variables that could be used to predict POV.
POV and/or PONV after craniotomy in children have not
been well described in the literature. Two small rand-
omized controlled trials of ondansetron, a 5-HT3 receptor
antagonist, have estimates of 24 hour POV in children
after craniotomy that range from 24% [11] to 66% [6],
whereas PONV in older children was estimated at 32%
[11]. Although some clinicians believe that the use of pro-
phylactic anti-emetics decreases the incidence of POV in
these children, neither study could show efficacy for intra-
operative administration of ondansetron in reducing chil-
dren's POV by 24 hours. Subramaniam et al. [10] could
not show evidence for an extra scheduled postoperative
dose of ondansetron either. Finally, intermittent dosing of
any class of anti-emetics does not appear to have been
studied in this patient population. In order to effectively
design such studies, knowledge of the incidence of PONV
and associated risk and protective factors must be first
established to know the extent of the problem and ensure
that the children at highest risk are targeted for prophy-
laxis.
Children who appear to be at high risk for nausea and
vomiting are those who require posterior fossa craniot-
omy. Posterior fossa surgery takes place below the tento-
rium cerebelli in the posterior cranial fossa. The posterior
cranial fossa houses structures that include: the cerebel-
lum; brainstem; and cranial nerves III-XII. Although the
reticulospinal tracts, diencephalon, limbic system, and
discrete areas of the cerebral hemispheres may all be
involved in nausea, retching, and vomiting, the coordina-
tion of the autonomic changes associated with retching
and vomiting occurs at the level of the medulla oblongata
in the posterior fossa [12-14]. Thus, from an anatomical
perspective, procedures that are proximal to this area may
place patients at especially high risk for vomiting. The
aforementioned studies in children after craniotomy
[6,11] have been too small to allow this conclusion to be
drawn, but studies in adults suggest that posterior fossa
procedures are related to greater postoperative nausea
(PON) [7] and PONV [15-17] when compared to
supratentorial procedures. However, Quiney and col-
leagues [18] prospectively examined nausea and vomiting
in 52 adults and children (aged 8–74) after craniotomy
and found that 37% of participants experienced severe
nausea or vomiting, while 35% experienced nausea at the
end of the 24 hour period. These authors could not find
any relationship between location of surgery and symp-
toms; however, their small sample size limits the validity
of this finding.
Children who require craniotomy form a heterogeneous
group. By specifically studying children after posterior
fossa surgery, the research questions can be focused on the
unique risk and protective factors for PONV for this group
of children, while limiting the heterogeneity in the sam-
ple. This approach has shown success in determining risk
and protective factors specific to the location of the neu-
rosurgery in adult studies [19-21]. Thus, the purpose of
this study was to describe PONV in children requiring
posterior fossa surgery, to explore risk and protective fac-
tors for PONV, and to examine the relationship of PONV
to adverse outcomes. Results could then be used to guide
the design of future studies and provide the rationale for
implementing improvements to clinical practice.
Methods
The hospital charts of children who required posterior
fossa surgery at two Canadian children's hospital sites, the
Stollery Children's Hospital in Edmonton and the Hospi-
tal for Sick Children in Toronto, were reviewed for the
study. A retrospective study design was chosen as an effi-
cient and cost effective way to describe nausea and vomit-
ing in this group of children. Specifically, for the acute
postoperative period, we sought to determine:
1) The cumulative incidence of nausea and vomiting by:
hours 4, 8, and 24; and during subsequent 24 hour peri-
ods.BMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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2) The frequency distribution of number of days that nau-
sea and vomiting were experienced.
3) The frequency distribution of number of vomiting
events.
4) The significant risk and protective factors for nausea
and vomiting.
5) The co-morbidities that children with nausea and vom-
iting experience.
Sample Selection & Sample Size Estimation
Following institutional ethical review and administrative
approval at each centre, all patients under age seventeen
who had posterior fossa surgery between March 1, 2001
and March 1, 2007 were identified for chart retrieval
through two separate paediatric neurosurgeons' databases
(Stollery Children's Hospital) and a central paediatric
neurosurgery database (Hospital for Sick Children). The
upper limit for age was determined by the age of qualifi-
cation for admission to both children's hospitals. Fourth
ventricular shunt procedures, operations without dural
openings (outside the brain), surgery for traumatic brain
injury, and children requiring prolonged intubation
(greater than 48 hours) were excluded. If more than one
posterior fossa procedure was required for a child over the
study period, the earliest one was included in the study.
Prospectively, we estimated data from two sites to involve
approximately 300 children. This would allow for an esti-
mation of incidence within a 6% margin of error [22]. It
would also allow for a multivariable analysis of 10–15
variables if the incidence of an outcome ranged from 30–
70%, which would allow for one independent variable
per ten outcomes [23].
Data Collection Procedures
A case report form was developed specifically for the study
in collaboration with a paediatric educator in surgery, a
neurosurgeon, and clinical nurse specialists/advanced
nurse practitioners in children's neurosurgery. Data were
collected by review of the child's in-patient chart. The data
collection period extended over the course of a child's
neurosurgical postoperative hospital stay, up to ten days.
Thus, data collection ended when the child went home,
was transferred from neurosurgical care to rehabilitation
care (i.e. to a rehabilitation hospital or rehabilitation
unit), was transferred from neurosurgery care to oncology
care for further treatments, or at 240 hours after the
recorded time that the anaesthetic was finished. The first
ten postoperative days were chosen by the study team to
ensure that an adequate length of time was captured for
the exploratory analysis. The final outcomes for analysis
of risk and protective factors were determined based on
these exploratory results.
One nurse with paediatric neurosurgical experience at
each site collected data. To ensure reliability, the two data
collectors trained on ten charts. Revisions to the data col-
lection form were then made as necessary. For example,
the child's activity and diet at each time period were ini-
tially part of the case report form. Due to gaps in charting,
these data could not be collected reliably. Once the case
report was finalized, each person then reviewed the same
five randomly selected charts to establish inter-rater relia-
bility: 100% inter-rater reliability was achieved for the
main study outcomes, independent variables and adverse
events. Weekly contact was maintained between the two
sites to discuss issues that arose during data collection.
Measurement
PONV covers one or more of three symptoms: nausea;
retching; and vomiting [24]. Nausea is the unpleasant sen-
sation of the urge to vomit that occurs along with neuro-
logical changes such as excessive salivation and
swallowing [25]. Each time nausea was charted in the
nurses' notes, it was recorded on the study case report
form. Documented children's statements or behaviours
that referred to nausea, such as states that he feels "like
throwing up" or "appears nauseous," were also included.
Retching is the first phase of vomiting [12] and is com-
monly defined as an unproductive attempt to vomit [25].
Vomiting is the forceful expulsion of stomach contents
through the mouth that involves coordinated autonomic
processes in the brain and gut [12]. Because of their simi-
lar physiology, retching and vomiting should be consid-
ered together in the data analysis, whereas nausea should
be considered separately [26]. To screen for retching and
vomiting events (POV), the post-anaesthesia recovery
room record was first reviewed, followed by the in and out
flow sheets. The time of the event was noted. The nurses'
notes and assessment flow charts were then read for fur-
ther events, for more accurate time of the event if it corre-
sponded to the in-and-out flow sheets, and to screen for
retching episodes. If retching and vomiting were docu-
mented at the same time, they were considered one event.
The medication administration records were reviewed and
anti-emetic administration was noted. If an anti-emetic
was administered, the nurses' notes were reviewed a sec-
ond time to look for a documented retching or vomiting
event around the time of the administration of the anti-
emetic. Administration of an anti-emetic was not consid-
ered indication of nausea, retching or vomiting.
Data on potential risk factors were collected from the
admission records, physician notes, anaesthesia records,
operative reports, and medication flow sheets. This data
included age of child, gender, presenting symptoms, type
of surgery, length of surgery, use of intraoperative dexam-
ethasone and/or ondansetron (administration at any timeBMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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after induction), and type of anaesthetic. For analysis, age
was examined in quartiles rounded to the year: 0 to <4; 4
to <7; 7 to <12; and 12 to <17. A number of variables were
dichotomized for analysis. The use of desflurane has been
shown to be a risk factor in adults requiring retromastoid
craniectomy, compared to other volatile anaesthetics [20].
We therefore examined the use of desflurane (alone or in
combination with another volatile anaesthetic) compared
to a grouping of all other volatile anaesthetics. This was
the only variable with missing values (n = 13; either
undocumented in the chart or illegible) and, due to the
likelihood that the missing value was not desflurane, we
included the missing values in the "other" category (the
mode was isoflurane). The use of nitrous oxide, a well
known risk factor for PONV [24], was rarely documented
for induction and not used for maintenance, and there-
fore was not assessed as in intraoperative risk factor. Intra-
operatively, ondansetron was the only anti-emetic used,
and dexamethasone the only steroid.
Finally, Potential co-morbidities, including development
of a pseudomeningocele, wound failure or cerebral spinal
fluid leak through the incision, and wound infection,
were noted by examining the nursing notes, physician
notes, discharge summary, and/or reasons for readmis-
sion to the neurosurgical service. Reports of postoperative
imaging studies were also reviewed for possible documen-
tation of a pseudomeningocele.
Data Analysis
Data analysis was conducted using SPSS Version 15.0 soft-
ware. Demographic and study variables were summarized
using descriptive statistics that were appropriate to their
level of measurement. Cumulative incidence (number of
children with at least one recorded event by the specified
time period/total number of children in the study) was
used to calculate outcomes at: 4, 8, and 24 hours, and for
subsequent 24 hour periods until the end of the study
period. The number of days that an outcome was experi-
enced was calculated by subtracting the time of the first
recorded event from the last recorded event, and was sum-
marized using a frequency distribution. A frequency distri-
bution was also used for counts of recorded events.
Univariate logistic regression was first conducted to exam-
ine the relationships between each variable and the out-
comes. Additionally, the clinical plausibility of an
interaction effect of ondansetron and dexamethasone was
tested using two steps. In the first step, the adjusted odds
ratios of ondansetron and dexamethasone were estimated
using multivariable logistic regression. Then, the interac-
tion term of ondansetron and dexamethasone was
entered in the second step.
The univariate analysis was followed by multivariable
logistic regression to examine important risk and protec-
tive factors for the outcomes while controlling for other
variables. To determine confounding effects, variables
were entered into the multivariable model in an a-priori
determined, hierarchical fashion based on sequential
events (Figure 1). If a variable grouping changed the
regression coefficients of a previously entered statistically
significant variable by ≥15%, it was considered to be con-
founding (i.e., related to both the variable and the out-
come). Conversely, if a variable that was not previously
statistically significant became so with a change of ≥15%,
that grouping was also considered confounding. Individ-
ual variables within that grouping were then tested indi-
vidually to examine their relationship to the confounded
variable.
In the final step, plausible interactions of statistically sig-
nificant variables were tested to determine if any moder-
ating effects were present (i.e., that the relationship that
one variable has with an outcome changes depending on
the value of another variable). The clinical plausibility of
dexamethasone and ondansetron administered together
vs. either drug administered alone were again tested using
Hierarchical model for variable entry into multivariable analy- sis Figure 1
Hierarchical model for variable entry into multivaria-
ble analysis. *Interaction terms tested will be intraoperative 
ondansetron and dexamethasone as well as combinations of 
plausible statistically significant variables from the multivaria-
ble model.
1. Site 
2. Child Characteristics  
• Age 
• Gender 
• Required Surgery 
3. Presenting Symptoms (Vomiting) 
4. Intraoperative Care 
• Use of Desflurane 
• Administration of 
Dexamethasone 
• Administration of 
Ondansetron 
• Length of Surgery 
5. Significant Interaction Terms* BMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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an interaction term in the larger multivariable models at
this time. Only statistically significant interactions were
included in the final model. Multicollinearity, associa-
tions among the independent variables in the model, was
reviewed by looking for correlations above 0.8 between
any two variables.
To finish the analysis, cross tabulations were used to
examine the relationship between the final outcomes and
other adverse events. The phi statistic (ϕ) for nominal by
nominal variables was used to summarize these relation-
ships. This statistic was also used to examine relationships
between categorical confounding variables, whereas a
Pearson's correlation (r) was used for continuous varia-
bles.
Results
Sample Characteristics
Table 1 contains a description of the study sample. A total
of 249 children met the criteria for the study, from 329
potential candidates who were identified from three neu-
rosurgery databases. Of those excluded, 23 were wrongly
coded as posterior fossa procedures in the database, 22
were intubated for more than 48 hours, 13 had Chiari I
bony decompressions without a dural opening, 13 had a
supratentorial component to their surgery (other than
EVD/shunt insertion), 7 had ventriculo-peritoneal shunt
procedures only, and 2 had no corresponding hospital
record.
Description of PON, POV and PONV
The cumulative incidence of PON, POV and PONV over
the first ten days is presented in Table 2. As shown in this
table, there was a discrepancy in the documentation of
PON and POV. Because we felt that PON was not reliably
measured and documented, the remainder of the data
analysis was refocused to examine POV. The frequency
distribution of the time from first recorded POV to last
recorded POV is presented in Figure 2. The frequency dis-
tribution of POV events that were recorded over the study
period is shown in Figure 3. These figures indicate that
there was considerable variation in length of time that
children experienced vomiting as well as number of
recorded events. Close to 47% of children experienced
vomiting over a time course greater than 24 hours, while
20% continued to vomit over a time course greater than
120 hours. Recorded events, shown in Figure 3, show a
positively skewed distribution with 23% children with no
events, 36% of children with only one to three recorded
events, and 41% with over three events.
Analysis of risk and protective factors
Based on the initial exploratory data analysis, we decided
to examine the risk and/or protective factors for two out-
comes: POV in the first 120 hours (the acute postoperative
period), and early (an event recorded by 24 hours or less)
compared to late POV (the first event occurring after 24
hours up to 120 hours). The decision to make the cut-off
for the acute postoperative period 120 hours, despite data
collection that went up to 240 hours, was to control for
confounding factors such as early discharge, the require-
ment for sedation for procedures or tests, or the need for
further surgery that were emerging in the data after 120
hours. After data collection, it was clear that some poten-
tial risk factors could not be reliably collected due to lack
of documentation or inconsistent documentation. These
included: a history of PONV in the child or family mem-
ber; a history or motion sickness; and pain rating.
The initial univariate logistic regressions (Table 3) indi-
cated that only Chiari I Malformation surgery was a statis-
tically significant risk factor for POV by 120 hours.
Additionally, children in the two middle age quartiles (4
to <7 and 7 to <12) showed lower odds of late vomiting
compared to early. Thus, while overall these children did
not have greater odds of vomiting, they were more likely
to have early vomiting than the other age groups. When
testing for an interaction effect for ondansetron and dex-
amethasone, the first step showed that, when controlling
for dexamethasone, ondansetron became positively pre-
dictive of POV by 120 hours. The second step showed that
the interaction effect (i.e. an enhanced effect of both drugs
together) of ondansetron and dexamethasone was not sig-
nificant.
In the first multivariable analysis (Table 4), controlling for
the other variables in the model, children with any use of
desflurane (compared to the grouping of children who
received either sevoflurane, isoflurane, or a combination
of these), who received intraoperative ondansetron, who
required Chiari I malformation surgery or who had sur-
gery at the Hospital for Sick Children site had an increased
likelihood of vomiting by 120 hours. Conversely, children
in the fourth age quartile (12 to <17) were less likely to
vomit by 120 hours. Finally, the significant interaction
term indicated that intraoperative ondansetron moder-
ated the likelihood of vomiting with desflurane by 120
hours. Thus, those children who received desflurane were
less likely to vomit if given intraoperative ondansetron
than were those who received desflurane without receiv-
ing intraoperative ondansetron.
There were a number of variables which appeared to con-
found the effects of previously entered variables in the
model. When the factor of whether or not a child pre-
sented with vomiting was added (Model 3), the odds ratio
for POV by 120 hours for Chiari I surgery increased. A
greater proportion of children with brain tumours pre-
sented with vomiting than those with Chiari I malforma-
tions or other procedures (72% vs. 5% vs. 7%, phi statisticBMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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Table 1: Sample characteristics
Parameter
Number of Patients 249
Site n(%)
Stollery Children's Hospital 55 (22.1%)
Hospital for Sick Children 194 (77.9%)
Length of hospital stay in days (Mean ± SD, Range) 11 (± 21, 2–305)
Age in years (Mean ± SD, Range) 7.6 ± 4.4, 0.3–-16.8
Age in Quartiles n(%)
0 to <4 years 65 (26.1%)
4 to <7 years 61 (24.5%)
7 to < 12 years 75 (30.1%)
12 to <17 years 48 (19.3%)
Male: Female (Ratio %) 128 (51.4%):121 (48.6%)
Surgery n(%)
Brain Tumour 153 (61.4%)
Chiari I Malformation 81 (32.5%)
Other 15 (6.0%)
Chiari II Malformation 7 (2.8%)
Vascular Malformation 4 (1.6%)
Cyst or Aspiration of Pus 4 (1.6%)
Presenting with vomiting n(%) 115 (46.2%)
Preoperative Dexamethasone n(%)1 136 (54.6%)
Intraoperative Ondansetron 117 (47.0%)
Without Dexamethasone 47 (18.9%)
Intraoperative Dexamethasone 131 (52.6%)
Without Ondansetron 61 (24.5%)
Intraoperative Ondansetron and Dexamethasone 70 (28.1%)
No intraoperative anti-emetic 71 (28.5%)
Length of surgery in hours (Mean ± SD, Range) 5:01 ± 2:10 (1:39–17:56)
Length of anaesthesia in hours (Mean ± SD, Range) 6:22 ± 2:20 (2:05–20:15)BMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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for correlation of nominal variables (ϕ) = .0.65, p < .001);
thus, controlling for whether or not the child presented
with vomiting proportionally decreased the odds of vom-
iting for children with brain tumours compared to those
with Chiari I malformations. The combined surgery cate-
gory of "other" was too small (n = 15) to determine if
there was similar effect. The odds ratio for hospital site
changed to being significantly greater for the Hospital for
Sick Children after the intraoperative variables were
entered (Model 4). Desflurane and intraoperative
ondansetron were used proportionately more at the Stol-
lery Children's Hospital than at the Hospital for Sick Chil-
dren (69% vs. 9% for use of desflurane, ϕ = 0.59, p < .001
and 62% vs. 43% for ondansetron, ϕ = -0.16, p = .01).
There were no differences between the sites for the use of
dexamethasone (ϕ = 0.08, p = .23) or length of surgery (r
= -0.02 p = .74). Thus, controlling for the combination of
intraoperative risk factors, notably any use of desflurane
and administration of intraoperative ondansetron,
resulted in a proportionately higher reduction in the risk
of vomiting by 120 hours at the Stollery Children's Hos-
pital compared to the Hospital for Sick Children. These
findings highlight the challenges that can be found in
types of procedures and/or sites with different propor-
tions of children exposed to potential risk and protective
factors.
Type of volatile anaesthetic n(%)
Isoflurane 126 (50.6%)
Desflurane 46 (18.5%)
Isoflurane + Sevoflurane 32 (12.9%)
Sevoflurane 22 (8.8%)
Isoflurane + Desflurane 8 (3.2%)
Sevoflurane + Desflurane 2 (0.8%)
Not recorded/not legible 13 (5.2%)
Use of Nitrous Oxide** 7 (2.8%)
Received Postoperative Anti-emetic (%) 199 (79.9%)
Opioid administration initiated by the first 24 hours (%) 228 (91.6%)
*All but one child who received preoperative dexamethasone had a brain tumour.
**For induction only as no nitrous oxide was used for maintenance of anaesthesia.
Table 1: Sample characteristics (Continued)
Table 2: Cumulative incidence of retching/vomiting, nausea and PONV
Hours from anaesthetic finish time
Total number of children with least one event recorded (Cumulative Percent)
0–4 0–8 0–24 0–48 0–72 0–96 0–120 0–144 0–168 0–192 0–216*
Retching/Vomiting 59
(23.7%)
75
(30.1%)
119
(47.8%)
153
(61.4%)
164
(65.9%)
174
(69.9%)
181
(72.7%)
186
(74.7%)
187
(75.1%)
190
(76.3%)
191
(76.7%)
Nausea ** 24
(9.6%)
32
(12.9%)
59
(23.7%)
84
(33.7%)
93
(37.3%)
98
(39.5%)
103
(41.4%)
105
(42.2%)
105
(42.2%)
106
(42.6%)
107
(43.0%)
PONV 69
(27.7%)
81
(32.5%)
134
(53.8%)
162
(65.1%)
172
(69.1%)
182
(73.1%)
189
(75.9%)
190
(76.3%)
191
(76.7)
194
(77.9%)
195
(78.3%)
PONV: First recorded nausea, retching or vomiting.
*No new recorded events after 216 hours.
**The differences between the incidence of nausea and retching/vomiting indicate that nausea is underestimated.BMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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Finally, the addition of the interaction term of any use of
desflurane and the administration of ondansetron (Model
5) also showed a change in the odds of POV by 120 hours
for children requiring Chiari I surgery to a statistically sig-
nificant result. However, there were no differences in the
proportion of children in the three surgery categories who
received both ondansetron and desflurane (13% vs. 17%
vs. 13%, ϕ = .06, p = .68). The interaction of intraoperative
ondansetron and dexamethasone was not statistically sig-
nificant when tested with this multivariable model.
The second multivariable modelling procedure (Table 5)
was used to look at early (within 24 hours of their anaes-
thetic finish time) vs. late vomiting (after the first 24
hours up to 120 hours. The results of this analysis indicate
that, controlling for the other variables in the model, chil-
dren who received desflurane were more likely to begin
vomiting within 24 hours of their anaesthetic finish time
(early vomiting) than those who received one in the
grouping of other volatile anaesthetics. Those in the two
middle age quartiles (ages 4 to <7 and 7 to <12) were also
more likely to start vomiting in the first 24 hours com-
pared to those under age 4 and 12 to <17. There was no
significant interaction between intraoperative administra-
tion of ondansetron and dexamethasone in this model
either.
Assessment for multicollinearity (Table 6), showed no
estimates with correlations above .80. These results are
suggestive that multicollinearity may not play a large role
in the statistical model. The statistically significant corre-
lations in this part of the statistical analysis correspond to
the results already identified in the assessment for con-
founding effects (i.e., variables in a model that are related
to each other and the outcome).
Co-morbidities
With the exception of infection, adverse events were fre-
quently reported in the sample. Because posterior fossa
syndrome is most commonly associated with brain
tumours, the relationship between posterior fossa syn-
drome and POV by 120 hours was examined for brain
tumours only. As shown in Table 7, there was no relation-
ship between POV by 120 hours and the development of
pseudomeningocele, wound failure or cerebral spinal
fluid leak, infection, or posterior fossa syndrome.
Discussion
The results of this study support our clinical experience
that POV is a common adverse outcome for children after
posterior fossa surgery. Overall, POV is common enough
to regard all children who require posterior fossa surgery
as being at high risk for the development of POV. When
Hours from first recorded retching or vomiting to last in the 240 hours Figure 2
Hours from first recorded retching or vomiting to last in the 240 hours.
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POV occurred, counts of vomiting events formed a posi-
tively skewed distribution in this sample. These results are
similar to those shown by the data collected by Rowley
and Brown [3] in their classic post-operative vomiting
study of 1183 children after surgery. Many children in
their sample experienced one or two episodes, with the
number of events that a child experienced quickly taper-
ing off. Rowley and Brown urged researchers to identify
the recurrent, frequent, and distressing vomiting that
fewer children experience but which results in significant
distress and negative consequences for recovery. In this
study, many children experienced greater than three
events and/or experienced vomiting for time periods
much longer than twenty four hours. This finding also has
to be in the context of the use of intra-operative ondanset-
ron for 47% of the children and use of postoperative anti-
emetics in 80% of the children. Thus, even with current
efforts to prevent and treat POV, it was a frequent, recur-
rent and potentially long-lasting problem in this sample
of children.
In this study, some variables were related to POV in chil-
dren after posterior fossa surgery. These results may lead
to the development of predictive tools or the identifica-
tion of areas for stratification for future research. They will
also help to identify challenges for future research, espe-
cially multi-site studies. That one hospital site showed
greater odds of POV by 120 hours, once intraoperative
variables were entered, highlights the difficulty in com-
paring between sites that may have varying intraoperative
practices. Type of surgery was significant, with children
requiring surgery for Chiari I Malformation more likely to
have POV by 120 hours than children requiring brain
tumour craniotomies and "other" procedures. Within the
category of brain tumour surgery, there may be children
who are at much higher risk for POV, balanced out by
those at lower risk. A secondary analysis of these data for
children with posterior fossa brain tumours, in particular,
would be useful.
That the oldest age quartile (12 to <17 years) emerged as
a protective factor for POV by 120 hours, once intraoper-
ative variables were controlled for, is consistent with
research in children following other types of surgery [27],
but has not been supported in research for POV after
craniotomy [11]. The two middle quartiles (ages 4 to <12
Number of recorded retching or vomiting events over the study period Figure 3
Number of recorded retching or vomiting events over the study period.
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Table 3: Univariate analysis
Variable POV by 120 Hours
Odds Ratio (95% CI)
Early (≤ 24 hours) vs.
Late POV1
Odds Ratio (95% CI)
1. Site
Stollery Children's Hospital 1.00 1.00
Hospital for Sick Children 1.74 (0.92–3.29) 1.71 (0.73–4.03)
2. Child Characteristics
Age
0 to <4 years 1.00 1.00
4 to <6 years 1.10 (0.48–2.49) 0.26 (0.11–0.64)**
7 to <12 years 0.90 (0.42–1.92) 0.30 (0.13–0.69)**
12 to <17 years 0.54 (0.24–1.23) 0.41 (0.16–1.08)
Female Gender 0.79 (0.45–1.38) 1.39 (0.74– 2.62)
Required Surgery
Brain Tumour 1.00 1.00
Chiari I Malformation 2.32 (1.17–4.60)* 0.60 (0.30–1.19)
Other 0.39 (0.13–1.13) 4.86 (0.90–26.30)
3. Presenting Symptom
Presenting with Vomiting 0.95(0.55–1.67) 1.09 (0.58–2.05)
4. Intraoperative Care
Administration of Ondansetron 1.78 (1.00–3.15) 0.74 (0.39–1.38)
Administration of Dexamethasone 0.65 (0.37–1.15) 1.62 (0.86–3.05)
Length of surgery 1.00 (0.98–1.01) 1.00 (0.98–1.01)
Use of Desflurane 1.32 (0.66–2.64) 0.34 (0.14–0.83)*
5. Test of Interaction: Ondansetron and
Dexamethasone
Adjusted Odds Ratio
(95% CI)
Adjusted Odds Ratio
(95% CI)
Step 1
Intraoperative ondansetron 1.92 (1.07–3.45)* 1.75 (1.91–3.35)
Intraoperative dexamethasone 0.59 (0.33–1.06) 0.66 (0.34–1.26)
Step 2BMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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years) were more likely to vomit earlier, but their odds of
vomiting were no different than those under four years of
age by 120 hours. Infants and young children in this
group of children may present later with vomiting and
"catch-up" to school aged children by 120 hours. This
result points to the importance of examining POV beyond
the first 24 hours and continuing prophylactic use of anti-
emetics beyond 24 hours in at-risk groups. Interestingly,
gender was not shown to be a significant risk factor and,
therefore, an interaction effect of gender and age was not
examined, despite the idea that females after puberty may
be at higher risk for POV [27].
While not desflurane was commonly used in this sample,
any use of desflurane was identified as a risk factor for
early vomiting compared to the use of other volatile
anaesthetics. This finding must be taken in the context of
a small sample size and very wide confidence intervals
when all other variables in the model were controlled for.
The Stollery Children's Hospital site had a greater propor-
tion of exposed children than the Hospital for Sick Chil-
dren and the influence of individual clinicians was not
accounted for. As previously discussed, the use of desflu-
rane has been identified as a significant risk factor when
compared to other volatile anaesthetics in a multivariable
analysis of risk factors for PONV for adults requiring
microvascular decompression of cranial nerves [20]; this
is why we chose to include it, and compare it to a group-
ing of other volatile anaesthetics (isoflurane, sevoflurane
and combinations of these) in the multivariable analysis.
The use of desflurane in children has the advantage of
rapid recovery [28] which must be clinically balanced
with any potential disadvantages in this clinical popula-
tion if chosen; however, its association with POV in this
study warrants reconsideration of its use when there are
other efficacious anesthetic options.
Children who received intraoperative ondansetron were
more likely to vomit by 120 hours those who did not. This
finding may be due to use of clinical judgment in admin-
istering ondansetron, a drug which has not been shown to
have efficacy in preventing vomiting in children after
craniotomy [6,11]. Thus, the administration of the drug
was predictive of vomiting due to its administration to
those correctly judged likely to vomit due to influences
not measured or included in the multivariable analysis.
Apfel and colleagues [4] also did not find a significant
effect for intraoperative anti-emetics in decreasing POV in
their multivariable logistic regression models. Interesting
is the significant moderating effect of the intraoperative
ondansetron on the use of desflurane as shown by the sig-
nificant interaction term in the first multivariable model.
Future studies of the efficacy of ondansetron, and other 5-
HT3 receptor antagonists, in preventing POV in this group
of children might then include stratification for character-
istics of the volatile anaesthetic used.
The intraoperative use of dexamethasone was not shown
to be a protective factor for POV by 120 hours. Like
ondansetron, its use may have been targeted to children
clinically perceived to be at high risk for POV, and so a
protective effect might not emerge in a retrospective study.
The lack of significance of the use of intraoperative dex-
amethasone and the lack of an interaction effect between
dexamethasone and ondansetron may also be reflective of
this limitation. Additionally, we did not control for the
use of preoperative dexamethasone because preoperative
dexamethasone was given to most of the children with
brain tumours, and thus collinearity with the type of sur-
gery would be a problem. However, Subramaniam and
colleagues [11] did look at preoperative dexamethasone
treatment in children with brain tumours in their rand-
omized controlled trial of ondansetron. These authors
found no difference in PONV between children who
received dexamethasone preoperatively and those who
did not. Length of surgery as a continuous variable was
also not a significant risk factor for POV by 120 hours in
this sample, which is consistent with previous research,
where the cut off for a protective effect for length of sur-
gery was 30 minutes [3,9].
Finally, associations between POV by 120 hours and a
number of negative consequences for recovery – the devel-
opment of a pseudomeningocele, infection, wound fail-
ure/cerebral spinal fluid leak, and posterior fossa
syndrome (in children with brain tumours) – could not
Intraoperative ondansetron 1.43 (0.58–3.53) 0.37 (0.13–1.03)
Intraoperative dexamethasone 0.49 (0.23–1.02) 1.10 (0.45–2.67)
Dexamethasone X ondansetron 1.63 (0.50–5.30) 2.86 (0.73–11.13)
1. Early vomiting coded as 0 and late as 1, no POV counted as missing therefore n = 181.
*p < .05
**p < .01
CI = Confidence Interval
Table 3: Univariate analysis (Continued)BMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
Page 12 of 17
(page number not for citation purposes)
Table 4: Multivariable analysis: POV by 120 hours
M o d e l  N u m b e r 5432 1
Variable Adjusted Odds Ratio
(95% CI)
Adjusted Odds Ratio
(95% CI)
Adjusted Odds Ratio
(95% CI)
Adjusted Odds Ratio
(95% CI)
Odds Ratio
(95% CI)
1. Site
Stollery Children's Hospital 1.00 1.00 1.00 1.00 1.00
Hospital for Sick Children 3.92
(1.45–10.58)*
4.25
(1.62–11.12)α**
1.78
(0.90–3.51)
1.78
(0.90–3.50)
1.74
(0.92–3.29)
2. Child Characteristics
Age in quartiles%
0 to <4 years 1.00 1.00 1.00 1.00
4 to <7 years 0.86
(0.35–2.14)
0.84
(0.34–2.06)
0.96
(0.41–2.27)
1.00
(0.43–2.35)
7 to <12 years 0.51
(0.21–1.22)
0.56
(0.24–1.31)
0.72
(0.32–1.61)
0.74
(0.33–1.64)
12 to <17 years 0.34
(0.13–0.88)*
0.33
(0.13–0.82)α*
0.48
(0.20–1.12)
0.47
(0.20–1.11)
Female Gender 0.64
(0.34–2.14)
0.66
(0.35–1.21)
0.71
(0.39–1.27)
0.69
(0.39–1.25)
Surgery
Brain Tumour 1.00 1.00 1.00 1.00
Chiari I Malformation 2.78
(1.03–7.50)*
2.43
(0.91–6.48)α
3.46
(1.48–8.10)α**
2.80
(1.37–5.71)**
Other 0.65
(0.31–1.35)
0.53
(0.14–1.99)
0.54
(0.17–1.79)
0.44
(0.15–1.35)
3. Presenting Symptoms
Presenting with Vomiting 1.75
(0.79–3.91)
1.63
(0.75–3.54)
1.40
(0.67–2.90)
4. Intraoperative Care
Administration of Ondansetron 3.47
(1.61–7.47)**
2.22
(1.14–4.33)*
Administration of Dexamethasone 0.65
(0.31–1.35)
0.58
(0.28–1.19)
Length of surgery 0.90
(.76–1.06)
0.91
(0.78–1.08)
Use of Desflurane 14.08
(2.47–80.32)**
3.11
(1.13–8.62)*BMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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be identified in the data. These outcomes may be better
studied prospectively with consideration of the severity of
POV. A prospective study would also aid in identifying a
causal pathway in the relationship between negative out-
comes and POV.
The primary limitation of this study is its retrospective
nature as it limits the researchers' control over the data
that can be collected. For the outcomes of nausea, vomit-
ing, and retching, the quality of the charting by health care
professionals was paramount. The exact count of vomit-
ing episodes was likely underestimated, as severe events
were often identified as "+ + + vomiting," but the cumula-
tive incidence of vomiting at the specified time period
should be accurate. Additionally, retching may have only
been charted if it occurred without vomiting, for example
in the post-anaesthesia recovery room or paediatric inten-
sive care. Once the child was cared for in the general nurs-
ing care unit, it may have been unobserved by the health
care team and thus not documented. Subjective measures
of nausea, expressed by the child, were rarely charted. In
adults after craniotomy, risk factors for nausea may be dif-
ferent than those for vomiting [7]. As we were unable to
evaluate risk and protective factors for nausea, the results
of this study can not be applied to PON.
There were also challenges in conducting the study at two
sites. Differences in the way that postoperative neurosur-
gical care was provided and the timing of transfer of the
child either home, for rehabilitation, or for oncology
treatment, varied between institutions. Different docu-
mentation styles and charting practices may have also
affected data collection. Defining what constituted the
acute postoperative period was also difficult and the out-
comes for analysis of risk and protective factors were
decided once the data were collected and descriptive sta-
tistics completed.
Sample size issues also became apparent in the final stages
of the multivariable analysis, as shown by the wide confi-
dence intervals for some variables. Initially we had esti-
mated a sample size of approximately 300. There were
more children with exclusion criteria than expected,
which decreased the final sample. The high incidence of
vomiting, even when the outcome was limited to POV by
120 hours, resulted in five children without vomiting per
variable for the final multivariable model. Therefore, the
results of the multivariable analysis should be interpreted
with caution and require further validation.
Due to the retrospective nature of the data collection, the
multivariable models developed in this study can be used
to identify risk and protective factors for POV in children
after posterior fossa surgery in general. The models were
not developed for prognosis or risk scoring at the individ-
ual level. The study does not show the effect of treatments,
only their contribution as possible risk or protective fac-
tors. The type of data that can be extracted is limited to
what is charted in a retrospective study. For example,
whether or not the administration of a postoperative anti-
emetic was prophylactic or therapeutic could not be relia-
bly determined and therefore was not used in the analysis.
A further limitation of the study is that the outcomes
examined for the risk and protective factors were one or
more events of POV by 120 hours and early vs. late POV.
Severity of POV, an important outcome that is often clin-
ically observed in children after posterior fossa surgery,
and may be inferred from the frequency of events and
length of time that POV was experienced, was not quanti-
fied for the analysis of risk and protective factors.
Conclusion
The findings of risk and protective factors in this study
support the suggestion that current prognostic models
and risk scoring systems for POV should not be used in
children after posterior fossa craniotomy [29] as they may
be different for this population. Given the descriptive
findings of how common POV is in this group of children
after posterior fossa surgery, guidelines such as those pro-
posed by The Society for Ambulatory Anesthesia [30] for
POV in high risk populations should be considered. These
guidelines include the use of two or three prophylactic
drugs from different classes for children who are at high
risk for POV and to consider the use of total intravenous
anaesthesia (TIVA). With established POV, drugs from
another class than that already in use ought to be consid-
ered. Importantly, in a Bayesian Meta-analysis of six single
drugs and five combinations, Engelman, Salengaros, and
Barvais [31] found the greatest relative risk reduction
(80%) in POV with the combination of the 5-HT3 receptor
antagonists and dexamethasone. Of particular note, is the
current absence of evidence that any class of drug, includ-
5. Significant Interaction
Use of Desflurane X Intraoperative
administration of ondansetron
0.10
(0.12–0.55)**
*p < .05
**p < .01
α Change ≥ 15% in a statistically significant variable or ≥ 15% making a variable statistically significant
CI = Confidence Interval
Table 4: Multivariable analysis: POV by 120 hours (Continued)BMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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Table 5: Multivariable analysis: Early vs. late POV (POV in the first 24 hours vs. after 24 hours to 120 hours)1
Model Number 4 3 2 1
Variable Adjusted Odds Ratio
(95% CI)
Adjusted Odds Ratio
(95% CI)
Adjusted Odds Ratio
(95% CI)
Odds Ratio
(95% CI)
1. Site
Stollery Children's Hospital 1.00 1.00 1.00 1.00
Hospital for Sick Children 0.72
(0.22–2.19)
1.80
(0.72–4.52)
1.80
(0.72–4.50)
1.71
(0.72–4.03)
2. Child Characteristics
Age in quartiles%
0 to <4 years 1.00 1.00 1.00
4 to <7 years 0.30
(0.11–0.79) *
0.31
(0.12–0.79)*
0.31
(0.12–0.78)*
7 to <12 years 0.31
(0.13–0.79)*
0.32
(0.13–0.77)*
0.32
(0.13–0.76)*
12 to <17 years 0.50
(0.17–1.48)
0.47
(0.17–1.30)
0.47
(0.17–1.29)
Female Gender 1.90
(0.93–3.91)
1.62
(0.81–3.21)
1.62
(0.82–3.21)
Required Surgery
Brain Tumour 1.00 1.00 1.00
Chiari I Malformation 0.64
(0.22–1.88)
0.64
(0.20–1.38)
0.57
(0.27–1.20)
Other 2.82
(0.39–20.70)
2.63
(0.40–16.19)
2.70
(0.45–16.14)
3. Presenting Symptom
Presenting with Vomiting 0.71
(0.26–1.84)
0.89
(0.36–2.17)
4. Intraoperative Care
Administration of Ondansetron 0.85
(0.40–1.80)
Administration of Dexamethasone 2.02
(0.87–4.68)
Length of surgery 1.00
(0.98–1.02)
Use of Desflurane 0.23
(0.07–0.73)*
1. Early vomiting coded as 0 and late vomiting coded as 1, n = 181.
*p < .05 **p < .01
α Change ≥ 15% in a statistically significant variable or ≥ 15% making a variable statistically significant CI = Confidence IntervalBMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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Table 6: Correlations among independent variables in the model
V a r i a b l e 123456 7 89 1 0 1 1 1 2
Site 1 1.00
4 to <6 years1 2 -.06 1.00
7 to <12 years1 3 .16 - 1.00
12 to <17 years1 4 -.08 - - 1.00
Female 5 -.03 -.03 .03 .03 1.00
Chiari I Malformation2 6 -.04 -.02 .01 .10 .15 1.00
Other2 7 -.07 -.07 -.09 .09 -.01 - 1.00
Presenting with Vomiting 8 .05 .11 .04 -.15 -.13 -.57* -.20* 1.00
Administration of Ondansetron 9 -.16 .01 .10 .11 .06 .03 -.10 .03 1.00
Administration of Dexamethasone 10 .08 .09 -.01 -.09 -.03 -.46* -.10 .40* .14 1.00
Length of surgery 11 .08 .09 -.01 -.09 -.02 .45* -.10 -.39* .14 .30* 1.00
Use of Desflurane 12 -.59 .01 -.12 -.13 .07 .04 -.02 -.08 .19 .03 .00 1.00
1. Reference category 0–<4
2. Reference category brain tumour surgery *Two tailed p < .01
Table 7: Relationship of POV by 120 hours to adverse outcomes
Vomiting by 120 hours
n (% total)
Phi Statistic
(Significance)
Total (n = 249) No Yes
Pseudomeningocele
No 49 (19.7) 124 (49.8)
Yes 19 (7.6) 57 (22.9) 0.03 (p = .59)
Would Failure/CSF Leak
No 55 (22.1) 158 (63.5)
Yes 13(5.2) 23 (9.2) -0.08 (p = .20)
Wound Infection
No 63 (25.3) 175 (70.3)
Yes 5 (2.0) 6 (2.4) -0.09 (p = .17)
Brain Tumour (n = 153)
Posterior Fossa Syndrome
No 34 (22.2) 82 (53.6)
Yes 13 (8.5) 24 (15.7) -0.05 (p = .50)BMC Nursing 2009, 8:7 http://www.biomedcentral.com/1472-6955/8/7
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ing the combination of dexamethasone and ondansetron,
is effective for preventing or treating POV in children after
craniotomy. Overall, this is a unique but understudied
population of children who are at risk for POV.
There have also not been any studies of particular anaes-
thetic protocols, such as TIVA with propofol, in children
requiring posterior fossa surgery. Knowledge and treat-
ment guidelines are currently limited to what is known in
other patient populations. Translating current knowledge
and treatment guidelines to children requiring posterior
fossa surgery is challenging. For example, even the results
of studies of TIVA in adults after craniotomy remain
inconclusive [32]. Finally, given the length of time that
children experience POV, it is necessary that protocols for
inpatient anti-emetic care, including length of time post-
operative dexamethasone is administered and the postop-
erative use of intermittent use of anti-emetics, be
developed and tested in children requiring posterior fossa
craniotomy. Ultimately, a methodical approach to pre-
venting and treating POV, starting in the preoperative
period, following through the child's course of care in the
hospital and included in discharge planning, is required
for this vulnerable group of children.
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